Estrogen receptor degradation: a CUE for endocrine resistance? by Musgrove, Elizabeth A
Background
Endocrine therapies that impair estrogen synthesis or 
interfere with estrogen receptor (ER) signaling are central 
to the standard of care for the 75% of breast cancers that 
are ER-positive, and these therapies, particularly the 
selective ER modulator tamoxifen, have made a signiﬁ  -
cant contribution to the recent reduction in breast cancer 
mortality [1]. Many women treated with endocrine 
therapy will experience disease progression during therapy 
or subsequent recurrence of their disease, however, and 
so understanding the molecular basis of endocrine 
resistance is a priority for improving the survival of 
breast cancer patients [1,2].
ERα expression is a major determinant of the success of 
endocrine therapy: immunohistochemically detectable 
ERα expression in >1% of cells is suﬃ   cient to predict 
clinical beneﬁ  t, and patients with the highest levels of 
ERα expression have the longest survival following 
endocrine therapy [3,4]. ERα levels are under complex 
regu  lation by transcription factors including multiple 
Fork  head family members, as well as ligand-mediated 
downregu  la  tion of ERα transcription and proteasomal 
degradation of the ERα protein [5-8]. However, the 
determinants of ERα levels in breast cancer are not 
completely understood. A recent publi  cation identiﬁ  es 
CUE domain-containing protein 2 (CUEDC2) as a new, 
and probably important, piece in this puzzle [9]. Th  e 
CUE domain is a ubiquitin-binding motif, which initiates 
proteolytic degradation of speciﬁ  c targets [10].
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Zhang and colleagues have shown that CUEDC2 binds 
both the progesterone receptor (PR) and ERα, resulting 
in degradation of these receptors and reduction of ligand-
activated gene transcription [9,11]. CUEDC2 binds PR 
through an interaction between the CUE domain and the 
N-terminal inhibitory function domain of PR, but binds 
ERα through an interaction between the N-terminal 
domain of CUEDC2 and the DNA binding domain of 
ERα [9,11]. Th  e CUE domain is not necessary for ERα 
binding, but is necessary for ubiquitination and degra  da-
tion of ERα [9].
To investigate the potential role of CUEDC2 in breast 
cancer, immunohistochemistry of a panel of markers 
including CUEDC2, ERα, PR, Ki67 and HER2 was used 
[9]. CUEDC2 was signiﬁ  cantly overexpressed in breast 
cancer compared with adjacent normal tissue, and breast 
cancers with the highest CUEDC2 staining (that is, 
strong staining in >50% of cells) were predominantly 
ERα-negative and PR-negative. Both overall and in the 
ERα-positive subgroup, CUEDC2 expression was inver-
sely related to ERα expression, although >20% of ERα-
positive cancers had low ERα levels despite low CUEDC2 
expression, or high levels of both proteins. High 
CUEDC2 expression was associated with reduced 
survival of ERα-positive patients following endocrine 
therapy (tamoxifen), but had no signiﬁ  cant relationship 
with patient outcome in ERα-positive patients who did 
not receive tamoxifen therapy or in ERα-negative 
patients. In breast cancer cells in culture, CUEDC2 
overexpression led to tamoxifen resistance. Th  is  could  be 
reversed by co-expression of ERα, suggesting that although 
CUEDC2 binds multiple targets, its eﬀ  ects on tamoxifen 
sensitivity are predominately mediated through ERα.
Abstract
Despite the undoubted success of adjuvant endocrine 
therapies that target the estrogen receptor pathway, 
not all women with estrogen receptor-positive breast 
cancer respond to these therapies, and many who 
initially respond will subsequently relapse. Deregulation 
of various aspects of estrogen receptor signaling has 
been highlighted as a mechanism of resistance and as a 
basis for alternative therapeutic approaches. However, a 
recent publication refocuses attention on the estrogen 
receptor itself by showing that the ubiquitin-binding 
CUE domain-containing protein 2 is a regulator of 
estrogen receptor protein degradation and a marker of 
endocrine resistance in breast cancer.
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Collectively the ﬁ  ndings of Zhang and colleagues indicate 
that CUEDC2 is an important regulator of ERα expres-
sion in breast cancer, and is a mechanistically-based 
biomarker of response to endocrine therapy. Importantly, 
unlike many other biomarkers that are correlated with 
patient outcome following tamoxifen treatment [2], 
CUEDC2 appears to be speciﬁ   cally associated with 
response to therapy, rather than with an inherently poor-
outcome phenotype [9]. One signiﬁ  cant implication of 
this work is that ERα mRNA levels may not necessarily 
be a good surrogate measure of ERα protein. Overall, ERα 
mRNA and protein are correlated in large breast cancer 
series, but determination of ER status by these measures is 
discordant in ~10% of cases, some of which are immuno-
histochemically ERα-negative despite express  ing readily 
detectable levels of ERα mRNA [12,13]. Over  expression of 
CUEDC2 could contribute to this discor  dance.
Several priorities for further investigation arise from 
these ﬁ  ndings. Although regulation of ERα protein levels 
was necessary for the ability of CUEDC2 overexpression 
to confer tamoxifen resistance in vitro, in multivariate 
analysis CUEDC2 was predictive of the outcome of 
tamoxifen therapy independent of ERα expression [9]. 
ERα may thus not be the only relevant target of CUEDC2 
in clinical breast cancer. Whether CUEDC2 regulates the 
degradation of steroid hormone receptors other than 
ERα and PR, and whether its expression is correlated 
with steroid receptor expression in hormone-dependent 
cancers other than breast cancer, are not known. How-
ever, CUEDC2 expression is reduced in castrate-recur-
rent prostate cancer, which is characterized by increased 
androgen receptor activity [14], suggesting CUEDC2 may 
also act to dampen androgen receptor signaling. In 
addition, there are no published data address  ing regula-
tion of CUEDC2 so it will be of signiﬁ    cant interest to 
determine how the protein’s expression and function are 
regulated in normal physiology, and to determine the 
mecha  nisms for the signiﬁ  cant overexpres  sion of CUEDC2 
in breast cancer. Finally, it will be important to dissect the 
functional interrelationships between CUEDC2 and the 
kinase LMTK3, recently iden  ti  ﬁ  ed as a negative regulator 
of ERα protein degradation that is also neces  sary for 
transcription of ERα mRNA and is correlated with endo-
crine resistance [15].
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